Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Epimab Biotherapeutics Co. Ltd. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is handled by examiner BRISTOL, LYNN ANNE, who is the busiest examiner for the company with 1 pending action. The portfolio is limited to 1 distinct examiner and 1 distinct art unit. For a practitioner, this means that the outcome of the company's current patent prosecution is entirely in the hands of a single examiner. There is no internal baseline to compare how different examiners might treat the company's technologies.
The presence of 1 pending office action indicates a very focused active portfolio. Because the action is in 1 distinct art unit, the practitioner can concentrate on the specific prior art and procedures relevant to that unit. BRISTOL, LYNN ANNE is the sole examiner currently engaged with the company's pending applications, so their specific perspective is the most important factor in the prosecution. The Biotechnology & Pharmaceuticals technology area points to innovations in biological or pharmaceutical systems. With 1 distinct examiner and 1 distinct art unit, the company's current patent profile is highly centralized.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18706263 | ANTI-CD122 ANTIBODIES, ANTI-CD132 ANTIBODIES, AND RELATED BISPECIFIC BINDING PROTEINS | BRISTOL, LYNN ANNE | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18706263 | ANTI-CD122 ANTIBODIES, ANTI-CD132 ANTIBODIES, AND RELATED BISPECIFIC BINDING PROTEINS | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | — | Pending | Apr 30, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Epimab Biotherapeutics Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Lynn Anne Bristol has the most, with 1 of Shanghai Epimab Biotherapeutics Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
